Abaloparatide
Proven to cut spine fractures; use is time-limited.
A newer bone-building daily injection that works through the same receptor as teriparatide. An made by Radius Health, Theramex, also called Tymlos and Eladynos.
What the evidence shows
Side effects and risks
Who should avoid it: Children and teenagers whose bones are still growing, and people with Paget's disease, past radiation to the skeleton, or bone tumors.
How it works
- Where it acts
- PTH1 receptors, in a way that favours bone building.
- What it changes
- It builds new bone.
- What people notice
- Fewer spine fractures. Dizziness, a fast heartbeat and high blood calcium can occur.
How it is taken
An 80 microgram injection under the skin once a day. The US label advises against more than two years in a lifetime. In the EU and UK the limit is 18 months.
Getting it in the United States
The legal route for Abaloparatide
Get a prescription from a licensed clinician. Fill it at a licensed pharmacy or through the maker's own direct service.
Prescription pen from pharmacy
Prescribed by a doctor as a 30-day pen kept refrigerated before first use. The label warns of bone cancer seen in rats and of dizziness or fast heartbeat soon after a dose.
Source: MedlinePlus drug information
Routes people use for any peptide in the United States
Telehealth prescribing
Online clinics prescribe after a questionnaire, sometimes with no live doctor visit, and mail the drug. FDA moved in February 2026 to restrict mass-marketed compounded copies and claims that they are generic equivalents.
Risk: Thin medical screening. Compounded versions are not reviewed by FDA for quality.
Covers: Approved GLP-1 drugs, compounded semaglutide and tirzepatide
Source: GZERO Media, Apr 2026
Clinical trial enrolment
The only lawful way to get an unapproved peptide drug with medical monitoring. ClinicalTrials.gov lists eligibility, sites and phone numbers. Researchers note recruitment is hard when people can buy the drug on the gray market instead of risking placebo.
Risk: Possible placebo assignment, strict eligibility and travel to a study site.
Covers: Investigational peptide drugs still in development
Source: NIH, finding a clinical trial
Routes people use for any peptide in the United States
Compounding pharmacy with prescription
A clinician prescribes and a pharmacy compounds. Twelve peptides left the FDA do-not-compound category in April 2026 and a panel backed six in July, but they are not yet formally eligible. Pharmaceutical-grade ingredient is scarce.
Risk: Legal status is unsettled until FDA rulemaking ends. Pharmacies may use research-grade ingredient.
Covers: BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon and similar
Source: Frier Levitt, Apr 2026
Med spas and weight-loss clinics
Very common. Secret shoppers called 75 clinics and med spas in two states after shortages ended. 92 percent offered compounded semaglutide and 87 percent tirzepatide, often mixed with B vitamins to look custom.
Risk: Four of 23 suppliers lacked sterile compounding licenses and four had disciplinary records.
Covers: Compounded semaglutide and tirzepatide
Source: American Med Spa Association on JAMA Health Forum study, Jul 2026
Concierge and longevity doctors
Cash-pay physicians build peptide plans for wealthy clients. Reporting from San Francisco says some source from overseas channels, domestic research-use-only sellers or the few compounding pharmacies that will supply clinicians.
Risk: A doctor's involvement does not guarantee a pharmaceutical-grade product.
Covers: BPC-157, thymosin alpha-1, Selank, Semax, CJC-1295, ipamorelin, retatrutide
Source: San Francisco Standard, Sep 2025
Cross-border purchase or import
FDA says importing drugs for personal use is illegal in most cases but it may not object to small personal quantities in limited situations. Reporting also describes people travelling to Mexico for injections.
Risk: Packages can be seized. Product origin and cold-chain handling are hard to check.
Covers: Approved prescription peptides sold abroad
Source: FDA, personal importation
Routes people use for any peptide in the United States
Research-chemical websites
Sites sell vials marked for research or not for human consumption, with no prescription. FDA says some ship direct to consumers with dosing directions, and it has sent warning letters. Retatrutide exists only through this route or trials.
Risk: Unknown identity, strength and sterility. No pharmacist or prescriber involved.
Covers: Retatrutide, semaglutide, tirzepatide, BPC-157 and most unapproved peptides
Source: FDA, unapproved GLP-1 drugs page
Direct orders from Chinese factories
Buyers message factory sales agents and pay by crypto or payment app. A minimum order of about ten vials pushes people to buy in bulk and share. A blockchain analysis found US buyers were the largest source of funds.
Risk: Many of the same vendors list fentanyl precursors. Lab reports sent by sellers cannot be verified.
Covers: GLP-1 copies, melanotan II, BPC-157, TB-500, GHK-Cu, epitalon
Source: TRM Labs, Oct 2026
Chat groups and social sellers
Dealers are found through Telegram, WhatsApp, Discord and influencer discount codes. In a May 2026 survey of 1,000 US users, 14.5 percent bought this way and three quarters asked an AI chatbot for dosing.
Risk: 45 percent of social media buyers in that survey reported an emergency or urgent care visit for a reaction.
Covers: Retatrutide and other research-use-only peptides
Source: The Ethos, May 2026
This describes what people do. It is not advice. The decision is yours.
More contextWhat public figures say, videos and articles, when options run out and the chemistry
What experts and influencers say
Paraphrased from the linked sources.
On US approval for men, stressed that a large share of hip fractures occur in men. The approval rested on a 12-month trial measuring spine bone density, not fractures.
Bruce MitlakSourceRecommends
Money: Executive of the manufacturer

Welcomed NICE's plan to recommend a second bone-building drug for women at highest fracture risk and said she hoped it would later become available for men.
Emma ClarkWebsiteRecommends
Photo source: bristol.ac.uk

Called the NHS approval a step forward but warned that patchy fracture liaison and diagnostic services mean about 90,000 people who need bone drugs will still miss out.
Source: Pharmaceutical Journal, 2024-08
Craig JonesWebsiteMixed view
Photo source: theros.org.uk

Said the committee heard from patients about living with fear of falls. NICE positioned the drug for people who did not respond to or cannot tolerate usual treatments.
Source: Pharmaceutical Journal, 2024-08
Jonathan BengerWebsiteRecommends
Photo source: nice.org.uk
Authorised it for postmenopausal women in 2022 but put it under additional monitoring, flagged a rise in heart rate after injection and required a safety study on cardiovascular events and deaths.
Source: EMA product page, updated 2024-04, 2022-12
European Medicines AgencySourceMixed view
Watch and read
Explainers, reporting and podcasts worth your time. Summaries are ours. No sellers.
Drug Trial Snapshot: TYMLOS
FDA
FDA consumer summary of Tymlos trials: a daily injection for postmenopausal women at high fracture risk, with fewer spine fractures than placebo.
Regulator's plain summary of who was studied
Abaloparatide Injection: MedlinePlus Drug Information
National Library of Medicine, NIH
Patient guide to abaloparatide (Tymlos) injection for osteoporosis, covering how it builds bone, precautions including bone cancer risk, pregnancy, side effects and storage.
Trusted NIH patient guide to the approved drug
When options run out
Uses people turn to when standard treatment has failed.
Men with severe osteoporosis
- Who
- Men at high fracture risk. The US label includes them. UK and EU approvals cover only women after menopause.
- Evidence
- A 228-man placebo-controlled trial showed a larger gain in spine bone density at 12 months. It did not measure fractures.
After usual osteoporosis drugs fail
- Who
- Women at very high fracture risk who did not respond to, or could not tolerate, standard treatments or the other bone-building drugs.
- Evidence
- NICE accepted it as an option in 2024 and estimated more than 14,000 people in England could benefit.
- Route
- NHS hospital specialist under NICE guidance
Source: Pharmaceutical Journal, 2024-08
Legal last-resort routes
Expanded access (compassionate use)
For a serious or life-threatening condition with no comparable alternative and no trial you can join. Your physician asks the company for the drug, then files with FDA and an ethics board. The company can refuse. Costs are often not insured.
Right to Try
For a life-threatening condition after approved options are exhausted and no trial is open to you. The drug must have finished Phase 1 and be in active development. Your doctor asks the manufacturer directly. FDA does not review requests.
Source: FDA, Right to Try
Trial finders
Search ClinicalTrials.gov by condition or drug name, check eligibility and call the listed site. ResearchMatch is a free NIH-funded registry that lets researchers find you. Discuss risks with your own clinician before enrolling.
Source: NIH, finding a clinical trial
Personal import for serious conditions
FDA may not object when a US citizen imports up to about three months of a drug for a serious condition with no effective US treatment, with written personal-use confirmation and a US doctor's details. It is discretion, not a right.
Source: FDA, personal importation
Patient-specific compounding
When the approved product cannot meet a specific need of an identified patient, a prescriber can order a compounded version from a licensed pharmacy. Lower price alone does not qualify. Ingredients must be pharmaceutical grade.
Amino-acid sequence
Ringed tiles are amino acids not found in natural proteins.
Questions people ask
How well does abaloparatide work?
Over 18 months, new spine fractures fell from 4.2% to 0.6%, and other fractures from 4.7% to 2.7%.
How is abaloparatide different from teriparatide?
It is a newer bone-building daily injection that works through the same receptor as teriparatide, in a way that favours bone building.
How long can you take abaloparatide?
The US label advises against more than two years in a lifetime. In the EU and UK the limit is 18 months.
What are the side effects of Tymlos?
Dizziness, a racing heart and nausea shortly after a dose, and raised calcium in blood and urine. Bone cancer (osteosarcoma) occurred in rats.
Is Tymlos approved for men?
In the US, Tymlos is approved for women and men at high risk of fracture. In the EU, Eladynos is for postmenopausal women.
Your notebook
Taking it? A ten-second daily check-in keeps a record of how you feel, to talk through with your clinician.
Sources
Structure: PubChem